ReviewCurrent cardiology reports2026
Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAtrial fibrillation (AF) and/or the need for oral anticoagulation (OAC) frequently coexist with stable chronic coronary syndrome (CCS). In this population, clinicians must carefully balance ischemic protection against bleeding risk. This review aims to synthesize available evidence and address whether antiplatelet therapy (APT) should be maintained on top of OAC in this specific subset. RECENT
findingsRecent trials have provided key evidence. AFIRE, EPIC-CAD, AQUATIC and ADAPT-AF-DES have all demonstrated that OAC monotherapy is not only non-inferior but also superior to combination therapy (OAC plus APT) in terms of net clinical benefit, with fewer major bleeding events and no increase in ischemic complications. The AQUATIC and AFIRE trials even showed an excess in mortality with prolonged combination therapy. Current evidence supports OAC alone as the preferred long-term antithrombotic strategy in patients with AF and stable CCS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.